Replies to post #108662 on Amarantus Bioscience Holdings Inc (AMBS)

[Riskreturn168]

Sccrbrg: I looked up the paragraph you're referring to in the latest Chairman's blog. You are confusing two tests. The LP002 "bridge" test will be completed by the end of Q3. Data from that test will help with the "specs" on the "validation test" that will be completed by the end of Q4. The "12 week validation test" being done in ICON's lab is what must be completed before we begin commercialization.

As Dr. Rubenfeld said in today's meeting: "We will be launching a diagnostic in 4 months. We're there!"

[brharris]

Previous deadline? The LP-002 data is due in the coming weeks as stated which also qualifies as being before the end of Q4. How else would GC have stated it in the blog? Should he break everything down week by week....not really a question.

SAN FRANCISCO and GENEVA, Sept. 12, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today announced that it has completed enrollment of the originally planned 72 patient LP-002 clinical study to assess the commercial feasibility of the company's flagship Alzheimer's blood diagnostic LymPro Test®. Amarantus previously released positive interim data from LP-002 on July 31, 2014 and expects to release data on the predictive value of individual LymPro markers (univariate) from the full cohort of 72 patients in the coming weeks.